Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
HIV-infected children, youth, and adults have lower bone mineral density (BMD) than would be
expected for HIV-uninfected people of similar age, weight and race. As the majority of
perinatally HIV-infected U.S. children are entering or in adolescence, the potential for
HIV-related impaired BMD during the adolescent peak of bone mass acquisition is of particular
concern. The primary purpose of this study was to compare changes from pre-treatment levels
of BMD of the lumbar spine after 24 and 48 weeks of alendronate treatment with placebo in
HIV-infected children and adolescents.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Treatments:
Alendronate Calcium Calcium Carbonate Vitamin D Vitamins